• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.

作者信息

Gormley Nicole J, Pazdur Richard

机构信息

From the Food and Drug Administration, Silver Spring, MD.

出版信息

N Engl J Med. 2018 Nov 8;379(19):1791-1795. doi: 10.1056/NEJMp1803602.

DOI:10.1056/NEJMp1803602
PMID:30403935
Abstract
摘要

相似文献

1
Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.多发性骨髓瘤中的免疫疗法联合应用——已知与未知
N Engl J Med. 2018 Nov 8;379(19):1791-1795. doi: 10.1056/NEJMp1803602.
2
[Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].埃罗妥珠单抗联合泊马度胺及地塞米松治疗多发性骨髓瘤
Internist (Berl). 2019 Jun;60(6):658-660. doi: 10.1007/s00108-019-0592-9.
3
Elotuzumab in multiple myeloma.埃罗妥珠单抗治疗多发性骨髓瘤
Lancet Oncol. 2018 Dec;19(12):e675. doi: 10.1016/S1470-2045(18)30854-4. Epub 2018 Nov 15.
4
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.埃罗妥珠单抗联合泊马度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.
5
Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.黑色素瘤序贯免疫治疗导致的非典型严重免疫相关不良反应。
Melanoma Res. 2015 Apr;25(2):178-9. doi: 10.1097/CMR.0000000000000132.
6
Isatuximab: First Approval.依沙妥昔单抗：首次获批
Drugs. 2020 Jun;80(9):905-912. doi: 10.1007/s40265-020-01311-1.
7
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.FDA 批准概要：达雷妥尤单抗治疗既往接受过一种治疗的多发性骨髓瘤。
Oncologist. 2017 Nov;22(11):1347-1353. doi: 10.1634/theoncologist.2017-0229. Epub 2017 Sep 13.
8
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.isatuximab联合泊马度胺及地塞米松治疗多发性骨髓瘤时的抗体干扰及反应动力学
Blood Cancer J. 2021 Oct 20;11(10):169. doi: 10.1038/s41408-021-00562-9.
9
Lenalidomide in multiple myeloma.来那度胺治疗多发性骨髓瘤
Expert Rev Anticancer Ther. 2015 May;15(5):491-7. doi: 10.1586/14737140.2015.1033407. Epub 2015 Apr 5.
10
Second elotuzumab triplet efficacious in MM.第二代埃罗妥珠单抗三联疗法对多发性骨髓瘤有效。
Nat Rev Clin Oncol. 2019 Feb;16(2):67. doi: 10.1038/s41571-018-0137-5.

引用本文的文献

1
Targeted immunotherapy: harnessing the immune system to battle multiple myeloma.靶向免疫疗法：利用免疫系统对抗多发性骨髓瘤。
Cell Death Discov. 2024 Jan 27;10(1):55. doi: 10.1038/s41420-024-01818-6.
2
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.不可调和的差异：缓解率、无进展生存期和总生存期之间的脱节
J Clin Oncol. 2023 May 20;41(15):2706-2712. doi: 10.1200/JCO.23.00225. Epub 2023 Mar 17.
3
Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma.
单独使用或联合帕博利珠单抗治疗复发/难治性多发性骨髓瘤的安全性和有效性。
Blood Adv. 2023 Apr 11;7(7):1168-1177. doi: 10.1182/bloodadvances.2022008460.
4
Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma.超越细胞：多发性骨髓瘤新型非细胞免疫治疗方法。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):173-179. doi: 10.1182/hematology.2022000335.
5
Bone marrow niche in multiple myeloma and its precursor states.多发性骨髓瘤及其前驱状态中的骨髓微环境。
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000246. eCollection 2019 Jun.
6
Practical guidance for new multiple myeloma treatment regimens: A nursing perspective.新型多发性骨髓瘤治疗方案的实用指南：护理视角。
Semin Oncol. 2022 Feb;49(1):103-117. doi: 10.1053/j.seminoncol.2022.01.010. Epub 2022 Feb 10.
7
Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond.肾功能不全的复发难治性多发性骨髓瘤患者的治疗进展：新型药物、免疫疗法及其他
Cancers (Basel). 2021 Oct 9;13(20):5036. doi: 10.3390/cancers13205036.
8
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors.考虑患者、疾病和治疗相关因素，为复发/难治性多发性骨髓瘤（RRMM）患者选择合适的治疗方法。
Cancers (Basel). 2021 Aug 26;13(17):4320. doi: 10.3390/cancers13174320.
9
Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.肿瘤负担通过细胞毒性疗法避免 T 细胞耗竭限制双特异性抗体疗效。
Blood Cancer Discov. 2021 Jul;2(4):354-369. doi: 10.1158/2643-3230.BCD-21-0038.
10
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.PD-1/PD-L1 抑制剂在肿瘤学中的系统评价：从个性化医疗到公共卫生。
Oncologist. 2021 Oct;26(10):e1786-e1799. doi: 10.1002/onco.13887. Epub 2021 Jul 27.